Quantinno Capital Management LP Has $14.31 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Quantinno Capital Management LP boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 27.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 252,908 shares of the biopharmaceutical company's stock after purchasing an additional 54,104 shares during the quarter. Quantinno Capital Management LP's holdings in Bristol-Myers Squibb were worth $14,305,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BMY. Truist Financial Corp boosted its holdings in shares of Bristol-Myers Squibb by 3.9% in the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after buying an additional 60,365 shares during the period. Contravisory Investment Management Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $488,000. Decker Retirement Planning Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $474,000. Corundum Group Inc. boosted its holdings in shares of Bristol-Myers Squibb by 67.8% in the fourth quarter. Corundum Group Inc. now owns 43,534 shares of the biopharmaceutical company's stock valued at $2,462,000 after buying an additional 17,596 shares during the period. Finally, High Net Worth Advisory Group LLC boosted its holdings in shares of Bristol-Myers Squibb by 42.2% in the fourth quarter. High Net Worth Advisory Group LLC now owns 16,974 shares of the biopharmaceutical company's stock valued at $960,000 after buying an additional 5,040 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Jefferies Financial Group reduced their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.96 on Friday, hitting $46.77. 12,103,063 shares of the stock were exchanged, compared to its average volume of 13,232,604. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The business's fifty day moving average is $53.05 and its 200 day moving average is $55.99. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a market capitalization of $95.18 billion, a PE ratio of -10.58, a P/E/G ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) earnings per share. The company's quarterly revenue was down 5.6% compared to the same quarter last year. Research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.